An observational study in Non Small Cell Lung Cancer, sponsored by Guangdong Association of Clinical Trials. Recruiting at 5 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-16.
Sponsored by Guangdong Association of Clinical Trials · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Carcinoma, Non-Small-Cell Lung by Guangdong Association of Clinical Trials — 10 open to participants now, 13 under way, none of them phase 3. Carcinoma, Non-Small-Cell Lung · Guangdong Association of Clinical Trials.
Among the 32 studies in Carcinoma, Non-Small-Cell Lung by Guangdong Association of Clinical Trials, this one is the 8th largest by planned enrollment of the 10 observational ones that give a count, is one of 2 that started in 2022, is one of 10 observational ones, reaches primary completion later than 5 of the 12 other live ones, and was the 22nd registered.
7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →10 of the 32 studies in Carcinoma, Non-Small-Cell Lung by Guangdong Association of Clinical Trials are open now, in 1 country. Recruiting first, the newest first:
Guangdong Association of Clinical Trials · Sites in China
Ages 18+
Guangdong Association of Clinical Trials · Sites in China
Ages 18+
Guangdong Association of Clinical Trials · Sites in China
Ages 18+
Guangdong Association of Clinical Trials · Sites in China
Ages 28–75
Guangdong Association of Clinical Trials · Sites in China
Ages 18–75
By country, each count listing its studies:
Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 15 · Phase 3 6 · Phase 4 1
First in 2011; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is above the median of 160 across 1,151 observational studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 118 across the 22 interventional studies, 358 across the 10 observational. Of the 8 that completed or were terminated, 1 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
Guangdong Association of Clinical Trials is the lead sponsor of 53 studies on the registry; 18 are open to participants now.
3 of the studies in Carcinoma, Non-Small-Cell Lung by Guangdong Association of Clinical Trials that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05457049Guangdong Association of Clinical TrialsAdjuvant Therapy Omission for Resected NSCLC Patients With Longitudinal Undetectable MRD | 2026-12-31 |
| NCT07696832Guangdong Association of Clinical TrialsEfficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort Study | 2027-05-15 |
| NCT07198841Guangdong Association of Clinical TrialsIBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 32 studies in Carcinoma, Non-Small-Cell Lung by Guangdong Association of Clinical Trials, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Molecular residual disease (MRD) has strong relationship with clinical outcome in multiple solid tumors. Here, the investigators try to verify the negative predictive value of undetectable MRD, which is considered as a superior prognostic factor for resected NSCLC patients, and not requiring excessive adjuvant therapy. Stage IB-IIIA resected NSCLC patients with landmark and longitudinal undetectable MRD are enrolled and under close surveillance in this study.
Stage IB-IIIA resected NSCLC patients will undergo two-round MRD tests after operation, first in 3-7 days and second in 1 month after operation. Patients who confirm two-round landmark undetectable MRD will be enrolled to be under close MRD and imaging monitoring without any adjuvant therapy. Patients who are MRD positive during the two-round MRD screening period will receive treatment and follow-up in accordance with Clinical Practice Guidelines.
Stage IB-IIIA NSCLC patients who after complete resection and undetectable landmark MRD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stage IB-IIIA NSCLC patients who after complete resection. And patients who maintain MRD negativity in two-round MRD landmark test (first in 3-7 days after surgery, second in 1 months ±7 days after surgery) will be enrolled. And patients will be under close dynamic monitoring at least two years.
Diagnostic Test: Molecular residual disease test
OncoMRD Lung
Two-years disease free survival rates for patients with longitudinal undetectable MRD
The 2-year DFS rate of patients who maintain 2-years undetectable MRD.
Time frame: 2 year
Two-years disease free survival rates for patients with six months longitudinal undetectable MRD
The 2-year DFS rate of patients who maintain 6-months undetectable MRD.
Time frame: 2 year
Two-years disease free survival rates for patients with 12-months longitudinal undetectable MRD
The 2-year DFS rate of patients who maintain 12-months undetectable MRD.
Time frame: 2 year
Two-years disease free survival rates for patients with 18-months longitudinal undetectable MRD
The 2-year DFS rate of patients who maintain 18-months undetectable MRD.
Time frame: 2 year
Two-years event-free survival rates for enrolled patients in two years
The events are defined as disease recurrence or detectable MRD.
Time frame: 2 year
Two-years disease free survival rates for patients who tested positive for MRD and failed screening during the two-round MRD tests.
The 2-year DFS rate of patients who tested positive for MRD and failed screening during the two-round MRD tests.
Time frame: 2 year
Plan to share: Undecided
Started Aug 2022 (actual). Primary completion is estimated for Dec 2026, 52 months after the start.
Of 358 non-industry observational studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 126. This study's planned 52 months is below that.
Counting every sponsor, half of 500 studies reached it within 55 months; a quarter within 35 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Non-Small-Cell Lung →
Guangdong Association of Clinical Trials